We showed previously that bacterially expressed full-length human wild-type p53b(1-393) binds selectively to supercoiled (sc)DNA in sc/linear DNA competition experiments, a process we termed supercoil-selective (SCS) binding. Using p53 deletion mutants and pBluescript scDNA (lacking the p53 recognition sequence) at native superhelix density we demonstrate here that the p53 C-terminal domain (amino acids 347-382) and a p53 oligomeric state are important for SCS binding. Monomeric p53(361-393) protein (lacking the p53 tetramerization domain, amino acids 325-356) did not exhibit SCS binding while both dimeric mutant p53(319- 393)L344A and fusion protein GCN4-p53(347-393) were effective in SCS binding. Supershifting of p53(320-393)-scDNA complexes with monoclonal antibodies revealed that the amino acid region 375-378, constituting the epitope of the Bp53-10.1 antibody, plays a role in binding of the p53(320-393) protein to scDNA. Using electron microscopy we observed p53-scDNA nucleoprotein filaments produced by all the C-terminal proteins that displayed SCS binding in the gel electrophoresis experiments; no filaments formed with the monomeric p53(361- 393) protein. We propose a model according to which two DNA duplexes are compacted into p53-scDNA filaments and discuss a role for filament formation in recombination.

Institute of Biophysics Academy of Sciences of the Czech Republic Kralovopolská 135 612 65 Brno Czech Republic

Zobrazit více v PubMed

Oren M. and Rotter,V. (1999) Introduction: p53—the first twenty years. Cell. Mol. Life Sci., 55, 9–11. PubMed PMC

Vogelstein B., Lane,D. and Levine,A.J. (2000) Surfing the p53 network. Nature, 408, 307–310. PubMed

Appella E. and Anderson,C.W. (2001) Post-translational modifications and activation of p53 by stresses. Eur. J. Biochem., 268, 2764–2772. PubMed

Albrechtsen N., Dornreiter,I., Grosse,F., Kim,E., Wiesmuller,L. and Deppert,W. (1999) Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene, 18, 7706–7717. PubMed

Hupp T.R. (1999) Regulation of p53 protein function through alterations in protein-folding pathways. Cell. Mol. Life Sci., 55, 88–95. PubMed PMC

Jayaraman L. and Prives,C. (1999) Covalent and noncovalent modifiers of the p53 protein. Cell. Mol. Life Sci., 55, 76–87. PubMed PMC

El-Deiry W.S., Kern,S.E., Pietenpol,J.A., Kinzler,K.W. and Vogelstein,B. (1992) Definition of a consensus binding site for p53. Nature Genet., 1, 45–49. PubMed

Bakalkin G., Selivanova,G., Yakovleva,T., Kiseleva,E., Kashuba,E., Magnusson,K.P., Szekely,L., Klein,G., Terenius,L. and Wiman,K.G. (1995) p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res., 23, 362–369. PubMed PMC

Dudenhoffer C., Kurth,M., Janus,F., Deppert,W. and Wiesmuller,L. (1999) Dissociation of the recombination control and the sequence-specific transactivation function of p53. Oncogene, 18, 5773–5784. PubMed

Szak S.T. and Pietenpol,J.A. (1999) High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain. J. Biol. Chem., 274, 3904–3909. PubMed

Jett S.D., Cherny,D.I., Subramaniam,V. and Jovin,T.M. (2000) Scanning force microscopy of the complexes of p53 core domain with supercoiled DNA. J. Mol. Biol., 299, 585–592. PubMed

Janus F., Albrechtsen,N., Knippschild,U., Wiesmuller,L., Grosse,F. and Deppert,W. (1999) Different regulation of the p53 core domain activities 3′-to-5′ exonuclease and sequence-specific DNA binding. Mol. Cell. Biol., 19, 2155–2168. PubMed PMC

Hainaut P., Hernandez,T., Robinson,A., Rodriguez-Tome,P., Flores,T., Hollstein,M., Harris,C.C. and Montesano,R. (1998) IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res., 26, 205–213. PubMed PMC

Zotchev S.B., Protopopova,M. and Selivanova,G. (2000) p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core. Nucleic Acids Res., 28, 4005–4012. PubMed PMC

Reed M., Woelker,B., Wang,P., Wang,Y., Anderson,M.E. and Tegtmeyer,P. (1995) The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl Acad. Sci. USA, 92, 9455–9459. PubMed PMC

Bakalkin G., Yakovleva,T., Selivanova,G., Magnusson,K.P., Szekely,L., Kiseleva,E., Klein,G., Terenius,L. and Wiman,K.G. (1994) p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl Acad. Sci. USA, 91, 413–417. PubMed PMC

Paleček E., Vlk,D., Stankova,V., Brazda,V., Vojtěšek,B., Hupp,T.R., Schaper,A. and Jovin,T.M. (1997) Tumor suppresor protein p53 binds preferentially to supercoiled DNA. Oncogene, 15, 2201–2209. PubMed

Mazur S.J., Sakaguchi,K., Appella,E., Wang,X.W., Harris,C.C. and Bohr,V.A. (1999) Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain. J. Mol. Biol., 292, 241–249. PubMed

Fojta M., Kubicarova,T., Vojtěšek,B. and Paleček,E. (1999) Effect of p53 protein redox states on binding to supercoiled DNA and linear DNA. J. Biol. Chem., 274, 25749–25755. PubMed

Paleček E., Brázdová,M., Brazda,V., Paleček,J., Billová,S., Subramaniam,V. and Jovin,T.M. (2001) Binding of p53 and its core domain to supercoiled DNA. Eur. J. Biochem., 268, 573–581. PubMed

Fojta M., Brázdová,M., Cernocka,H., Pečinka,P., Brazda,V., Paleček,J., Jagelska,E., Vojtěšek,B., Pospisilova,S., Subramaniam,V. et al. (2000) Effects of oxidation agents and metal ions on binding of p53 to supercoiled DNA. J. Biomol. Struct. Dyn., Sp. Iss. S1, 177–184. PubMed

Kirkegaard K. and Wang,J.C. (1985) Bacterial DNA topoisomerase I can relax positively supercoiled DNA containing a single-stranded loop. J. Mol. Biol., 185, 625–637. PubMed

Zechiedrich E.L. and Osheroff,N. (1990) Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers. EMBO J., 9, 4555–4562. PubMed PMC

Stros M. and Reich,J. (1998) Formation of large nucleoprotein complexes upon binding of the high-mobility-group (HMG) box B-domain of HMG1 protein to supercoiled DNA. Eur. J. Biochem., 251, 427–434. PubMed

Midgley C.A., Fisher,C.J., Bartek,J., Vojtěšek,B., Lane,D. and Barnes,D.M. (1992) Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J. Cell Sci., 101, 183–189. PubMed

Cho Y., Gorina,S., Jeffrey,P.D. and Pavletich,N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265, 346–355. PubMed

Sambrook J., Fritsch,E.F. and Maniatis,T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Waterman J.L., Shenk,J.L. and Halazonetis,T.D. (1995) The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J., 14, 512–519. PubMed PMC

Cherny D.I., Striker,G., Subramaniam,V., Jett,S.D., Paleček,E. and Jovin,T.M. (1999) DNA bending due to specific p53 and p53 core domain-DNA interactions visualized by electron microscopy. J. Mol. Biol., 294, 1015–1026. PubMed

Hupp T.R., Meek,D.W., Midgley,C.A. and Lane,D.P. (1992) Regulation of the specific DNA binding function of p53. Cell, 71, 875–886. PubMed

Brázdová M., Kizek,R., Havran,L. and Paleček,E. (2002) Determination of glutathione-S-transferase traces in preparations of p53 C-terminal domain (aa320–393). Bioelectrochemistry, 55, 115–118. PubMed

Brazda V., Paleček,J., Pospisilova,S., Vojtěšek,B. and Paleček,E. (2000) Specific modulation of p53 binding to consensus sequence within supercoiled DNA by monoclonal antibodies. Biochem. Biophys. Res. Commun., 267, 934–939. PubMed

Hupp T.R. and Lane,D.P. (1995) Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J. Biol. Chem., 270, 18165–18174. PubMed

Pospisilova S., Brazda,V., Amrichova,J., Kamermeierova,R., Paleček,E. and Vojtěšek,B. (2000) Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay. J. Immunol. Methods, 237, 51–64. PubMed

Ellenberger T.E., Brandl,C.J., Struhl,K. and Harrison,S.C. (1992) The GCN4 basic region leucine zipper binds DNA as a dimer of uninterrupted alpha helices: crystal structure of the protein-DNA complex. Cell, 71, 1223–1237. PubMed

Maru Y., Afar,D.E., Witte,O.N. and Shibuya,M. (1996) The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain. J. Biol. Chem., 271, 15353–15357. PubMed

Cherny D.I. and Jovin,T.M. (2001) Electron and scanning force microscopy studies of alterations in supercoiled DNA tertiary structure. J. Mol. Biol., 313, 295–307. PubMed

Paleček E., Brázdová,M., Cernocka,H., Vlk,D., Brazda,V. and Vojtěšek,B. (1999) Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments. Oncogene, 18, 3617–3625. PubMed

Paleček E. (1991) Local supercoil-stabilized DNA structures. Crit. Rev. Biochem. Mol. Biol., 26, 151–226. PubMed

Lyubchenko Y.L. and Shlyakhtenko,L.S. (1997) Visualization of supercoiled DNA with atomic force microscopy in situ. Proc. Natl Acad. Sci. USA, 94, 496–501. PubMed PMC

Yakovleva T., Pramanik,A., Kawasaki,T., Tan-No,K., Gileva,I., Lindegren,H., Langel,U., Ekstrom,T.J., Rigler,R., Terenius,L. et al. (2001) p53 latency. C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences. J. Biol. Chem., 276, 15650–15658. PubMed

Stenger J.E., Mayr,G.A., Mann,K. and Tegtmeyer,P. (1992) Formation of stable p53 homotetramers and multiples of tetramers. Mol. Carcinog., 5, 102–106. PubMed

Pavletich N.P., Chambers,K.A. and Pabo,C.O. (1993) The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev., 7, 2556–2564. PubMed

Shuman S., Bear,D.G. and Sekiguchi,J. (1997) Intramolecular synapsis of duplex DNA by vaccinia topoisomerase. EMBO J., 16, 6584–6589. PubMed PMC

Lee S., Cavallo,L. and Griffith,J. (1997) Human p53 binds Holliday junctions strongly and facilitates their cleavage. J. Biol. Chem., 272, 7532–7539. PubMed

Sturzbecher H.W., Donzelmann,B., Henning,W., Knippschild,U. and Buchhop,S. (1996) p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J., 15, 1992–2002. PubMed PMC

Prabhu V.P., Simons,A.M., Iwasaki,H., Gai,D., Simmons,D.T. and Chen,J. (2002) p53 blocks RuvAB promoted branch migration and modulates resolution of Holliday junctions by RuvC. J. Mol. Biol., 316, 1023–1032. PubMed

Susse S., Janz,C., Janus,F., Deppert,W. and Wiesmuller,L. (2000) Role of heteroduplex joints in the functional interactions between human rad51 and wild-type p53. Oncogene, 19, 4500–4512. PubMed

1,3-Diketone-Modified Nucleotides and DNA for Cross-Linking with Arginine-Containing Peptides and Proteins

Squaramate-Modified Nucleotides and DNA for Specific Cross-Linking with Lysine-Containing Peptides and Proteins

p53 Binds Preferentially to Non-B DNA Structures Formed by the Pyrimidine-Rich Strands of GAA·TTC Trinucleotide Repeats Associated with Friedreich's Ataxia

p53 Specifically Binds Triplex DNA In Vitro and in Cells

Wild-type p53 binds to MYC promoter G-quadruplex

Solvatochromic fluorene-linked nucleoside and DNA as color-changing fluorescent probes for sensing interactions

Differential salt-induced dissociation of the p53 protein complexes with circular and linear plasmid DNA substrates suggest involvement of a sliding mechanism

Azidophenyl as a click-transformable redox label of DNA suitable for electrochemical detection of DNA-protein interactions

Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells

Cruciform structures are a common DNA feature important for regulating biological processes

Change of the protein p53 electrochemical signal according to its structural form - quick and sensitive distinguishing of native, denatured, and aggregated form of the "guardian of the genome"

Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin